Urologie pro praxi 3/2019
Immunotherapy in the treatment of urological malignancies
The efficacy of novel immunotherapeutics, particularly checkpoint inhibitors, hold promise for a wide variety of tumor types in uro-oncology. This development is perhaps best illustrated by the current treatment for patients with metastatic renal cell carcinoma and urothelial cancer. Further development of biomarkers for predicting therapeutical response is required to achieve optimal efficacy with these therapeutic interventions.
Keywords: immunotherapy, renal cell cancer, prostate cancer, urothelial cancer.
